This prospective study enrolled healthcare workers (HCWs) who were nonresponders following at least 5 doses of aluminum-adjuvanted hepatitis B vaccine who received the 2-dose Heplisav-B (HepB-CpG) (Dynavax Technologies Corporation, Emeryville, CA) series. After 2 doses of HepB-CpG, 43/47 (91%) participants, and with 1 dose, 41/49 (84%) responded. HepB-CpG could be the preferred vaccine in HCW nonresponders. Clinical Trials Registration. Clinicaltrials.gov NCT04456504.

中文翻译：

---

乙型肝炎-CpG 疫苗系列，适用于乙型肝炎疫苗无反应的医护人员


这项前瞻性研究招募了在接种至少 5 剂铝佐剂乙型肝炎疫苗后无反应且接受 2 剂 Heplisav-B （HepB-CpG） 的医护人员 （HCW）（Dynavax Technologies Corporation，Emeryville，CA）系列。接种 2 剂 HepB-CpG 后，43/47 （91%） 参与者，接种 1 剂后，41/49 （84%） 有反应。HepB-CpG 可能是 HCW 无反应者的首选疫苗。临床试验注册。Clinicaltrials.gov NCT04456504。